Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kaneka Corporation (4118.T)
Tokyo, JP
Kaneka Corporation, established in Tokyo, Japan, in 1949, operates internationally as a diversified manufacturer providing a wide array of advanced materials and specialized products. Its core chemical business includes the production and global distribution of various polyvinyl chloride (PVC) formulations, such as crosslinked, paste, and chlorinated PVC, alongside acryl grafted-vinyl chloride copolymers. The company also supplies critical additives like impact modifiers, processing aids, specialty additives, and tougheners for thermosetting resins. Furthermore, their portfolio features advanced polymers including silyl-terminated polyether, acrylic silicon, terminally reactive liquid acrylic, biodegradable polymers, and engineering resins designed for injection molding, in addition to zero birefringence materials, acrylic films, and isobutylene-based thermoplastic elastomers. Beyond chemicals, Kaneka manufactures specialized foams and films, encompassing polypropylene and Kanelite foams, extruded polystyrene insulation, polyimide films, and transparent films for optical applications. Their material science expertise extends to high thermal conductive graphite sheets, multi-layer insulation, transparent conductive films, and transparent resins engineered for exceptional heat and light resistance. In the energy and innovative products sector, Kaneka offers photovoltaic power generation systems suitable for residential, public, and industrial installations. Other cutting-edge developments include eco-friendly fur, flame-retardant materials, hair accessories, novel materials, organic EL lighting panels, and biosurfactants. Their life sciences division delivers a comprehensive range of medical and pharmaceutical offerings, which include intervention and blood purification systems, gastroenterology intervention tools, diagnostic testing equipment, regenerative medicine and cell therapy solutions, and genetic diagnostics. Additionally, they provide low molecular pharmaceutical raw materials, affinity chromatography resins for monoclonal antibody purification, biopharmaceuticals, transdermal medicines, and innovative shock-absorbing innerwear. Lastly, Kaneka is a significant player in the food and nutrition industry. Their extensive product line features dairy products, margarines, fats and oils, whipping creams, fillings, baking essentials (baker's yeast, dough improvers), processed fruits, butter, shortening, cacao butter alternatives, various creams, frozen dough, spices, and antifreeze materials. They also supply pharmaceutical and supplemental nutrition solutions, such as coenzyme Q10, lactic-acid bacteria, and functional foodstuffs, alongside agricultural fertilizers.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.09% | +8.63% | +7.78% | +7.30% | +28.36% | +20.55% | +43.82% | +38.60% | +17.32% | +18.10% | -1.02% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+0.6% Q1'26: +4.5% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+25.0% ★ Q1'26: +70.0% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+0.2% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+3.9% Q1'26: +4.4% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+3.3% Q1'26: +4.2% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-2.1% ★ Q1'26: -2.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×2.93× Q1'26: 2.71× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 6 Rev. Ana. 4 EPS Ana. |
Mar 2027 3 Rev. Ana. 4 EPS Ana. |
Mar 2028 5 Rev. Ana. 5 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
552.19B
est: 558.56B (-1.1%)
|
555.23B
est: 557.97B (-0.5%)
|
548.22B
est: 552.20B (-0.7%)
|
596.14B
est: 605.87B (-1.6%)
|
621.04B
est: 624.63B (-0.6%)
|
601.51B
est: 603.74B (-0.4%)
|
577.43B
est: 568.16B (+1.6%)
|
691.53B
est: 687.40B (+0.6%)
|
755.82B
est: 754.98B (+0.1%)
|
762.30B
est: 777.94B (-2.0%)
|
807.20B
est: 803.66B (+0.4%)
|
809.10B
801.58B – 815.32B
+0.7% YoY
|
849.50B
845.69B – 851.56B
+5.0% YoY
|
883.50B
844.61B – 955.66B
+4.0% YoY
|
867.00B
845.56B – 904.29B
-1.9% YoY
|
879.50B
857.75B – 917.33B
+1.4% YoY
|
| EBITDA |
48.88B
est: 58.62B (-16.6%)
|
65.16B
est: 58.56B (+11.3%)
|
61.49B
est: 57.96B (+6.1%)
|
67.10B
est: 63.59B (+5.5%)
|
68.65B
est: 65.56B (+4.7%)
|
59.86B
est: 63.37B (-5.5%)
|
64.35B
est: 59.63B (+7.9%)
|
82.07B
est: 72.15B (+13.8%)
|
74.05B
est: 79.24B (-6.6%)
|
72.86B
est: 79.87B (-8.8%)
|
83.70B
est: 82.51B (+1.4%)
|
83.07B
82.30B – 83.71B
+0.7% YoY
|
87.22B
86.83B – 87.43B
+5.0% YoY
|
90.71B
86.71B – 98.12B
+4.0% YoY
|
89.01B
86.81B – 92.84B
-1.9% YoY
|
90.30B
88.06B – 94.18B
+1.4% YoY
|
| EBIT |
24.64B
est: 27.20B (-9.4%)
|
38.22B
est: 27.17B (+40.7%)
|
33.17B
est: 26.89B (+23.3%)
|
36.25B
est: 29.50B (+22.9%)
|
36.04B
est: 30.42B (+18.5%)
|
24.97B
est: 29.40B (-15.1%)
|
27.55B
est: 27.67B (-0.4%)
|
43.56B
est: 33.47B (+30.1%)
|
33.94B
est: 36.76B (-7.7%)
|
31.41B
est: 36.79B (-14.6%)
|
39.04B
est: 38.00B (+2.7%)
|
38.26B
37.91B – 38.56B
+0.7% YoY
|
40.17B
39.99B – 40.27B
+5.0% YoY
|
41.78B
39.94B – 45.19B
+4.0% YoY
|
41.00B
39.99B – 42.76B
-1.9% YoY
|
41.59B
40.56B – 43.38B
+1.4% YoY
|
| Net Income |
18.03B
est: 13.87B (+30.1%)
|
20.99B
est: 19.93B (+5.3%)
|
20.48B
est: 17.47B (+17.3%)
|
21.57B
est: 19.39B (+11.2%)
|
22.24B
est: 20.75B (+7.2%)
|
14.00B
est: 13.62B (+2.8%)
|
15.83B
est: 13.77B (+15.0%)
|
26.49B
est: 26.31B (+0.7%)
|
23.01B
est: 23.00B (+0.1%)
|
23.22B
est: 26.01B (-10.7%)
|
25.31B
est: 24.91B (+1.6%)
|
29.96B
25.68B – 32.28B
+20.3% YoY
|
27.27B
26.63B – 27.95B
-9.0% YoY
|
30.83B
27.27B – 33.38B
+13.1% YoY
|
36.83B
35.22B – 38.43B
+19.5% YoY
|
38.28B
37.05B – 40.42B
+3.9% YoY
|
| SGA |
87.32B
est: 101.96B (-14.4%)
|
91.97B
est: 101.85B (-9.7%)
|
96.31B
est: 100.80B (-4.5%)
|
99.01B
est: 110.60B (-10.5%)
|
104.41B
est: 114.02B (-8.4%)
|
107.86B
est: 110.21B (-2.1%)
|
105.54B
est: 103.71B (+1.8%)
|
115.97B
est: 125.48B (-7.6%)
|
123.86B
est: 137.82B (-10.1%)
|
128.40B
est: 141.30B (-9.1%)
|
137.85B
est: 145.97B (-5.6%)
|
146.96B
145.59B – 148.09B
+0.7% YoY
|
154.30B
153.60B – 154.67B
+5.0% YoY
|
160.47B
153.41B – 173.58B
+4.0% YoY
|
157.47B
153.58B – 164.25B
-1.9% YoY
|
159.74B
155.79B – 166.61B
+1.4% YoY
|
| EPS |
267.60
est: 218.95 (+22.2%)
|
314.90
est: 314.76 (+0.0%)
|
308.60
est: 275.83 (+11.9%)
|
328.45
est: 306.25 (+7.2%)
|
339.14
est: 327.65 (+3.5%)
|
214.69
est: 215.15 (-0.2%)
|
242.68
est: 217.38 (+11.6%)
|
406.00
est: 415.40 (-2.3%)
|
349.59
est: 364.37 (-4.1%)
|
357.90
est: 402.75 (-11.1%)
|
400.91
est: 396.88 (+1.0%)
|
477.25
414.11 – 520.51
+20.3% YoY
|
442.63
429.45 – 450.74
-7.3% YoY
|
507.03
439.72 – 538.14
+14.5% YoY
|
586.80
567.94 – 619.61
+15.7% YoY
|
617.20
597.36 – 651.71
+5.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-01 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan Opportunities Fund OPPJ | 0.90% | 2.52M | 0.58% |
| 2 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.29% | 1.11M | 0.58% |
| 3 | Avantis International Small Cap Value ETF AVDV | 0.21% | 39.68M | 0.36% |
| 4 | Vanguard Global Value Factor ETF VVL.TO | 0.16% | 913.2K | 0.38% |
| 5 | Dimensional - International Small Cap Value ETF DISV | 0.13% | 6.15M | 0.42% |
| 6 | Vanguard Global Value Equity Active ETF VVLU.AX | 0.13% | 1.12M | 0.28% |
| 7 | State Street SPDR S&P International Small Cap ETF GWX | 0.11% | 938.0K | 0.40% |
| 8 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.11% | 604.9K | 0.58% |
| 9 | FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund TLTD | 0.10% | 672.9K | 0.41% |
| 10 | WisdomTree International SmallCap Dividend Fund DLS | 0.10% | 1.07M | 0.58% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kazuhiko Fujii | President & Representative Director | 99M | male |
| Atsushi Kawakatsu | Managing Executive Officer, Manager of Takasago Industry Office & Manager of Nishi Plant | — | — |
| Jun Enoki | Managing Executive Officer & Director | — | male |
| Kazuo Ochiai | Managing Executive Officer | — | — |
| Keiji Suzuki | Executive Officer & Accounting Department Manager | — | — |
| Mamoru Kadokura | Executive Vice President & Director | — | male |
| Shinichiro Kametaka | Executive Vice President & Director | — | male |
| Shinji Mizusawa | Managing Executive Officer | — | male |
| Akira Iwazawa | Senior Managing Corporate Executive Officer & Manager of Production Technology Dept. | — | male |
| Yoshiki Takeoka | Managing Executive Officer & Manager of Global Planning | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4118.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
